The effect of the angiotensin converting enzyme inhibitor enalapril on dogs with moderate to severe heart failure due to insufficiency of the mitral valves. A clinical evaluation;Die behandlung der mitralklappeninsuffizienz des hundes mit dem ACE-hemmer enalapril

Tierarztliche Praxis Ausgabe K: Kleintiere - Heimtiere

Volumn 26, Issue 1, 1998, Pages 21-30

  Biller, Birgit ^a   Hörauf, Angelika ^a   Kraft, W ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

ACE inhibitors; Dog; Enalapril; Mitral insufficiency

Indexed keywords

CANIS FAMILIARIS; DIGITALIS;

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; DOG; DOG DISEASE; DRUG COMBINATION; DRUG EFFECT; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; MITRAL VALVE REGURGITATION; MULTIVARIATE ANALYSIS; TIME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIURETICS; DOG DISEASES; DOGS; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ENALAPRIL; FUROSEMIDE; MITRAL VALVE INSUFFICIENCY; MULTIVARIATE ANALYSIS; TIME FACTORS;

EID: 0031993143     PISSN: 14341239     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Benitz AM, Hamlin RL, Ericsson GF. Titration of enalapril dose for dogs with induced heart failure. J Vet Intern Med 1991; 5: 124 (abstr).
2. Bonagura JD, O'Grady MR, Herring DS. Echocardiography: principles of interpretation. Vet Clin North Am: Small Anim Pract 1985; 15: 1177-94.
3. Braunwald E. ACE inhibitors - a cornerstone of the treatment of heart failure. N Engl J Med 1991; 325: 351-3.
4. Buchanan JW. Chronic valvular disease (endocardiosis) in dogs. Adv Vet Sci Comp Med 1977; 21: 75.
5. Cleland JG, Dargie HJ, Me Alpine H et al. Severe hypotension after first dose of enalapril in heart failure. Br Med J 1985; 291: 1309-12.
6. Cohn JN, Levine TB, Olivari MT. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-23.
7. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
8. COVE Study Group. Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group. J Vet Int Med 1995; 9: 243-52.
9. Das KM, Tashjian RJ. Chronic mitral valve disease in the dog. Vet Med Small Anim Clin 1965; 60: 1209-16.
10. Davies RO, Irvin JD, Kramsch DK et al. Enalapril: worldwide experience. Am J Med 1984; 77 (Suppl IV): IV23-IV35.
11. De Zeeuw D, Navies GJ, Donker AJ, De Jong PE. The angiotensin converting enzyme inhibitor enalapril and its effects on renal function. J Hypertens 1983; 1 (Suppl 1): l93-l7.
12. Detweiler DK, Patterson DF. The prevalence and types of cardiovascular disease in dogs. Ann NY Acad Sci 1965; 127: 481-516.
13. Diez R, Waas W, Süsselbeck T et al. Improvement of cardiac function by angiotensin converting enzyme inhibition: Sites of action. Circulation 1993; 87 (Suppl IV): IV108-IV16.
14. Ettinger SJ, Suter PF. Canine Cardiology. Philadelphia, London, Toronto: Saunders 1970.
15. Fouad FM, Nakashima Y, Tarazi RC, Salcedo EE. Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa. Lack with association with blood pressure control. Am J Cardiol 1982; 49: 795.
16. Gomez HJ, Cirillo VJ, Davies RO et al. Enalapril in congestive heart failure: acute and chronic invasive hemodynamic evaluation. Int J Card 1986; 11: 37-48.
17. Grandi AM, Venco A, Barzizza F et al. Effect of enalapril on left ventricular mass and performance in essential hypertension. Am J Cardiol 1989; 63: 1093-7.
18. Haberbosch W. Improvement of diastolic filling in hypertensive patients treated with a new ACE-inhibitor (Cilazapril). Am J Hypertens 1990; 8 (Suppl 3): III1-III143.
19. Hamlin RL, Benitz AM, Ericsson GF et al. Effects of enalapril on exercise tolerance and longevity in dogs with heart failure produced by iatrogenic mitral regurgitation. J Vet Int Med 1996; 10: 85-7.
20. Henry WL, De Maria A, Gramiak R. Report of The American Society of Echocardiography Committee on nomenclature and standards in two-dimensional echocardiography. Circulation 1979; 62 (2): 212-7.
21. Hofmann S, Kersten U. Die Wirksamkeit und Sicherheit von Ramipril im Vergleich mit Captopril in der Behandlung der Herzinsuffizienz des Hundes. Dtsch Tierärztl Wochenschr 1996; 103 (5): 159-63.
22. IMPROVE Study Group. Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril Study. J Vet Int Med 1995; 9: 234-42.
23. Jahrmärkter H. Neuer BGA-Zulassungstext für Captopril und Enalapril bei Herzinsuffizienz. Arzneimitteltherapie 1992; 2: 33.
24. Joy MD, Lowe RD. Evidence that the area postrema mediates the central cardiovascular response to angiotensin II. Nature 1970; 228: 1303-4.
25. Keene BW. Chronic valvular disease in the dog. In: Canine and Feline Cardiology. Fox PR, ed. New York: Livingstone 1988; 409-18.
26. Kittleson MD, Eyster GE, Knowlen G et al. Myocardial function in small dogs with chronic mitral regurgitation and severe congestive heart failure. J Am Vet Med Assoc 1984; 184: 455-9.
27. Kittleson MD. Management of heart failure: concepts, therapeutic strategies and drug pharmacology. In: Canine and Feline Cardiology. Fox PR, ed. New York: Livingstone 1988; 171-204.
28. Kjekshus J, Swedberg K für die CONSENSUS Trial Study Group. Tolerability of enalapril in congestive heart failure. Am J Cardiol 1988; 62: 67A-72A.
29. Kjekshus J, Swedberg K, Snapinn S für die CONSENSUS Trial Study Group. Effects of enalapril on long-term mortality in severe congestive heart failure. Am J Cardiol 1992; 69: 103-7.
30. Kraft W, Dürr U, Hrsg. Klinische Labordiagnostik in der Tiermedizin. 3. Aufl. Stuttgart, New York: Schattauer 1995.
31. Linz W, Schölkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens 1989; (A) 11: 1325-50.
32. Mac Donald JS, Bagdon WJ, Peter CP. Renal effects of enalapril in dogs. Kidney International 1987; 31 (Suppl 20): XX148-XX53.
33. Mayer E, Dietz R, Richardt G, Schömig A. Noradrenalin release is modulated by angiotensin and salt in rat heart. Circulation 1986; 74 (Suppl 2): II376 (abstr.).
34. Mc Fate Smith W, Kulaga SF, Moncloa F et al. Overall tolerance and safety of enalapril. J Hypertens 1984; 2 (Suppl 2): 113-7.
35. Morisse B, Kersten U. Die Behandlung der Herzinsuffizienz des Hundes mit ACE-Hemmern: Quinapril und Captopril im Vergleich. Tierärztl Prax 1995; 23: 489-96.
36. Motz W, Klepzig M, Leschke M et al. Regression der Herzhypertrophie unter Saluretika? Klin Wochenschr 1987; 65 (Suppl 1): I176.
37. Motz W, Strauter BE. Rückbildung der hypertensiven Herzhypertrophie durch chronische Angiotensin-Konversions-enzymhemmung. Z Kardiologie 1988; 77: 53-60.
38. Norusis MJ. SPSS Advanced Statistics 6.1. SPSS Inc., Chicago 1994.
39. Norusis MJ. SPSS für Windows. Anwenderhandbuch für das Base System Version 6.0. SPSS Inc., Chicago 1994.
40. Osterziel KJ, Dietz R, Mikulaschek K et al. Vergleich von Captopril und Enalapril bei der Therapie der Herzinsuffizienz: Einfluß auf Hämodynamik und Nierenfunktion. Z Kardiologie 1988; 77: 378-84.
41. Packer M. How should physicians view heartfailure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol 1993; 71: 3C-11C.
42. Packer M. Neurohormonal interactions and adaptations in congestive heartfailure. Circulation 1988; 77 (4): 721-30.
43. Pang KS, Cherry WF, Tertell JA, Ulm EH. Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Drug Metabol Dispos 1984; 12: 309-13.
44. Pang KS, Cherry WF, Ulm EH. Disposition of enalapril in the perfused rat intestine-liver preparation: absorption, metabolism, and first-pass effect. J Pharmacol Exp Ther 1985; 233: 788-95.
45. Pedersen HD, Koch J, Poulsen K et al. Activation of the renin-angiotensin system in dogs with asymptomatic and mildly symptomatic mitral valvular insufficiency. J Vet Int Med 1995; 9: 328-31.
46. Pfeffer MA. Survival after an experimental myocardial infarction: beneficial effects of longterm therapy with captopril. Circulation 1985; 72: 406-12.
47. Rector TS, Olivari MT, Levine TB. Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. Am Heart J 1987; 114: 148-52.
48. Sahn DJ, De Maria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-Mode echocardiography. Results of a survey of echocardiographic measurements. Circulation 1980; 58: 1072.
49. Sil P, Kandaswamy V, Sen S. Role of angiotensin II on myocyte growth. Circulation 1995; 92 (Suppl 1): 164.
50. Thomas WP, Gaber CE, Jacobs GJ et al. Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. J Vet Int Med 1993; 7: 247-52.
51. Tobias R, Kersten U. Zur Therapie der Herzinsuffizienz des Hundes mit ACE-Hemmern. Kleintierpraxis 1992; 37: 19-22.
52. Tocco DJ, De Luna FA, Duncan AEW et al. The physiological disposition and metabolism of enalapril maleate in laboratory animals. Drug Metab Dispos 1982; 10: 15-9.
53. Van Zwieten PA, De Jong A. Interaction between the adrenergic and renin-angiotensin-aldosterone-system. Postgrad Med 1986; J. 62: 23-7.
54. Ware WA, Lund DD, Subieta AR. Sympathetic activation in dogs with congestive heart failure caused by chronic mitral disease and dilated cardiomyopathy. J Am Vet Med Assoc 1990; 197: 1475-81.
55. Whiteney JC. Observations on the effect of age on the severity of heart valve lesions in the dog. J Small Anim Pract 1974; 15: 511-22.
56. Wollam GL, Hall DW, Porter VD et al. Time course of regression of left ventricular hypertrophy in treated hypertensive patients. Am J Med 1983; 76: 100.